je.st
news
Tag: phase
Activated Carbon Adsorbers For Liquid And Vapor Phase Applications
2015-10-28 15:05:59| pollutiononline Products
Evoqua Water Technologies supplies activated carbon adsorbers and systems for both liquid and vapor phase applications, designed to treat a wide variety of flow rates and pressure requirements.
Tags: applications
phase
liquid
carbon
Harmonic Filter suits single phase power applications.
2015-10-27 13:31:05| Industrial Newsroom - All News for Today
Offered in 240 V and 480 V for applications spanning 3–150 hp, Matrix® ONE reduces THID to acceptable levels, optimizing power quality in rural, remote areas where it is often not optimal. Filter minimizes heat generation while providing protection needed to extend service life of electrical equipment.
Tags: power
single
applications
phase
Mercury Electronics Europe Offers New Microminiature Differential LVDS Oscillators With Low Integrated Phase Jitter
2015-10-27 07:23:09| rfglobalnet Home Page
Mercury Electronics Europe has introduced three new ranges of surface mount microminiature differential LVDS oscillators that offer femtosecond integrated phase jitter. Offering high performance at highly competitive prices, the new HDK series oscillators also offer superior phase noise.
Tags: low
offers
electronics
europe
AkzoNobel Outlines Next Phase Towards Leading Performance
2015-10-27 06:00:00| Coatings World Breaking News
Tags: performance
leading
phase
outlines
Merck to Present New Data on Investigational Chronic Hepatitis C Treatment Elbasvir/Grazoprevir at The Liver Meeting 2015, Including Phase 3 Results in Selected Difficult-to-Treat Populations
2015-10-20 16:35:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. New Data Will Also be Presented from Phase 2a C-CREST Trials of Mercks Investigational Triple-Combination Chronic Hepatitis C Therapies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data from clinical trials of its investigational treatment portfolio for chronic hepatitis C virus (HCV) are scheduled to be presented at The Liver Meeting 2015 (the 66th annual scientific congress of the American Association for the Study of Liver Diseases) in San Francisco, from Nov. 13-17, 2015. Mercks late-stage investigational portfolio includes elbasvir/grazoprevir1, MK-36822 and MK-84083. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 908-740-1871orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
including
data
present
Sites : [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] next »